Q-Therapeutics Obtains First U.S. Patent for Astrocyte Family of Neural Cells

Another emerging biotechnology company to keep an eye on in the ALS stem cell therapy arena is Salt Lake City, Utah-based Q-Therapeutics. The company has just been granted its first U.S. patent in its fifth family of patents on neural cells, which covers the astrocyte family of neural cells of the central nervous system (CNS). The company’s transplanted stem cell-derived astrocytes can provide both trophic support and reduce inflammation, and in addition have the capacity to provide long lasting treatment effects. Since defective astrocytes are implicated in many neurodegenerative diseases, these cells have potential for a wide range of indications. The lead inventor on the patents is Dr. Mahendra Rao, who is also the scientific founder and Chief Strategy Officer of Q-Therapeutics. The company is first aiming to treat ALS and expects to submit its first investigational new drug (IND) in 2014 (see Apr 2014 News).

Another emerging biotechnology company to keep an eye on in the ALS stem cell therapy arena is Salt Lake City, Utah-based Q-Therapeutics. The company has just been granted its first U.S. patent in its fifth family of patents on neural cells, which covers the astrocyte family of neural cells of the central nervous system (CNS). The company’s transplanted stem cell-derived astrocytes can provide both trophic support and reduce inflammation, and in addition have the capacity to provide long lasting treatment effects. Since defective astrocytes are implicated in many neurodegenerative diseases, these cells have potential for a wide range of indications. The lead inventor on the patents is Dr. Mahendra Rao, who is also the scientific founder and Chief Strategy Officer of Q-Therapeutics. The company is first aiming to treat ALS and expects to submit its first investigational new drug (IND) in 2014 (see Apr 2014 News).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail